Monitor early Auvelity Alzheimer's agitation adoption data (NBRx trends, prescriber activation) over the next 2-3 quarters for sustained growth signal. Watch for topline ENGAGE (BED) results in Q4 2026 and AXS-12 PDUFA in May 2027 as key pipeline catalysts.
Drugs in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this 8-K- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
Price Chart
Executive Summary
Axsome Therapeutics reported Q2 2026 total net product revenue of $218.4M (+46% YoY), driven by AUVELITY ($180.3M, +51% YoY) and SUNOSI ($35.8M, +20% YoY). The net loss widened to $51.3M (-$0.99 EPS) from $48.0M (-$0.97 EPS) a year ago, as SG&A surged 60% to $208.1M due to the Alzheimer's agitation launch and sales force expansion. The company has no guidance change, but early Auvelity Alzheimer's launch data (126% NBRx increase in 65+ patients) and AXS-12 PDUFA date (May 1, 2027) are positive pipeline catalysts. Despite revenue growth, expanding losses and rising costs keep the sentiment neutral.
Key Financial Metrics
Key Facts
- Q2 2026 total net product revenue $218.4M, +46% YoY from $150.0M
- AUVELITY net sales $180.3M (+51% YoY); 266,000 total prescriptions (+34% YoY, +12% QoQ)
- SUNOSI net revenue $35.8M (+20% YoY); ~61,000 prescriptions (+14% YoY, +8% QoQ)
- SYMBRAVO net sales $2.3M (461% YoY growth from low base); ~23,500 prescriptions
- Net loss $51.3M (-$0.99/share) vs $48.0M (-$0.97/share) YoY; includes $27.1M stock-based compensation
- SG&A expenses $208.1M, +60% YoY, driven by Alzheimer's launch activities and SYMBRAVO commercialization
- Cash $319.9M at June 30, 2026, down from $322.9M at Dec 31, 2025
- AUVELITY launched for Alzheimer's agitation in June 2026; NBRx 65+ patients up 126% in first 8 weeks
- AXS-12 NDA for narcolepsy cataplexy accepted; PDUFA May 1, 2027
- FOCUS-2 and FOCUS-3 pediatric ADHD Phase 3 trials for solriamfetol initiated
- No change to financial guidance; cash expected to fund operations into cash flow positivity
- Shares outstanding 52,299,889 at June 30, 2026
Financial Impact
Revenue growth of $68.4M YoY (+46%) driven by Auvelity and Sunosi; net loss widened by $3.3M; cash burn $3.0M in H1 2026
Risk Factors
- SG&A spend continues to outpace revenue growth (60% vs 46%); profitability timeline uncertain
- Auvelity Alzheimer's agitation launch is early; sustained demand growth not yet confirmed
- No specific numerical guidance provided; reliance on vague 'cash flow positivity' target
- Competitive pipeline risk from existing CNS drugs and other late-stage entrants
- Dilution from 1.4M share increase since end of 2025 (option exercises, equity issuances)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341206 |
| Document: axsm-20260810.htm | 0001193125-26-341206 |
| Document: axsm-ex99_2.htm | 0001193125-26-341206 |
| Document: 0001193125-26-341206-index-headers.html | 0001193125-26-341206 |
| Document: 0001193125-26-341206-index.html | 0001193125-26-341206 |
| Document: 0001193125-26-341206.txt | 0001193125-26-341206 |
| 8-K Data (Synthetic) | 0001193125-26-341206 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 Viewing No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers